This company has been marked as potentially delisted and may not be actively trading. NASDAQ:ECYT Endocyte (ECYT) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Endocyte Stock (NASDAQ:ECYT) 30 days 90 days 365 days Advanced Chart Get Endocyte alerts:Sign Up Key Stats Today's Range$23.99▼$23.9950-Day Range N/A52-Week Range$2.81▼$24.00VolumeN/AAverage Volume2.12 million shsMarket Capitalization$1.97 billionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Endocyte, Inc., a biopharmaceutical company, develops targeted therapies for the treatment of cancer and inflammatory diseases in the United States. The company uses its technology to create novel small molecule drug conjugates (SMDCs) and companion imaging agents. It is developing Vintafolide, a SMDC that is in Phase IIb clinical trial to treat non-small cell lung cancer; EC1456, which is in Phase I dose escalation trial for the treatment of advanced solid tumors; and EC1169, a tubulysin therapeutic that is in Phase I dose escalation trial to treat advanced metastatic castration-resistant prostate cancer. The company's products in pre-clinical development include EC2629, a folate receptor-targeted SMDC for use in treating cancer; EC2319 for the treatment of inflammatory diseases; EC0371 for treating polycystic kidney disease; and SMDC bi-specific adaptor chimeric antigen receptor T-cell for the treatment of immunotherapy in cancer. Endocyte, Inc. has a collaboration agreement with Purdue Research Foundation; Master License Agreement with Purdue Research Foundation; Merck Sharp & Dohme Research GmbH; and Nihon Medi-Physic Co., LTD. The company was founded in 1995 and is headquartered in West Lafayette, Indiana. Read More Receive ECYT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Endocyte and its competitors with MarketBeat's FREE daily newsletter. Email Address ECYT Stock News HeadlinesTelix Pharmaceuticals Ltd (TLX)February 16, 2024 | investing.com'The most exciting company in Australia': The ASX stock up 179% in 6 monthsJanuary 3, 2024 | fool.com.auA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again. July 6 at 2:00 AM | Porter & Company (Ad)The Endocyte Bear Thesis: Why March Will be a Bad MonthMay 17, 2023 | thestreet.comWhy Endocyte (ECYT) Stock Is Plummeting in After-Hours Trading TodayJanuary 5, 2023 | thestreet.comGlobal Pharmaceutical Contract Manufacturing Market is projected to reach a market value of US$329.7 Billion in 2032: Visiongain Reports Ltd - Yahoo FinanceSeptember 20, 2022 | finance.yahoo.comPurdue University impacting lives: successfully delivering innovations to the public - GlobeNewswireJune 6, 2022 | globenewswire.comGlobal Chronic Myeloid Leukemia Pipeline Insight | Clinical Trials Evaluation Research Report 2022 by DelveInsight - GlobeNewswireMay 23, 2022 | globenewswire.comSee More Headlines ECYT Stock Analysis - Frequently Asked Questions How were Endocyte's earnings last quarter? Endocyte, Inc. (NASDAQ:ECYT) issued its quarterly earnings data on Wednesday, November, 7th. The biopharmaceutical company reported ($0.17) EPS for the quarter, missing the consensus estimate of ($0.16) by $0.01. The biopharmaceutical company had revenue of $0.09 million for the quarter, compared to the consensus estimate of $0.02 million. Endocyte had a negative net margin of 32,296.09% and a negative trailing twelve-month return on equity of 21.19%. What other stocks do shareholders of Endocyte own? Based on aggregate information from My MarketBeat watchlists, some other companies that Endocyte investors own include Bristol Myers Squibb (BMY), Meta Platforms (META), Gilead Sciences (GILD), Advanced Micro Devices (AMD), Micron Technology (MU), Netflix (NFLX) and NVIDIA (NVDA). Company Calendar Last Earnings11/07/2018Today7/06/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryPharmaceuticals Current SymbolNASDAQ:ECYT CIK1235007 Webwww.endocyte.com Phone765-463-7175FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Trailing Twelve Months)($1.00) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$55.06 million Net Margins-32,296.09% Pretax MarginN/A Return on Equity-21.19% Return on Assets-20.55% Debt Debt-to-Equity RatioN/A Current Ratio45.80 Quick Ratio45.80 Sales & Book Value Annual Sales$70 thousand Price / Sales28,133.42 Cash FlowN/A Price / Cash FlowN/A Book Value$1.99 per share Price / Book12.06Miscellaneous Outstanding Shares82,090,000Free FloatN/AMarket Cap$1.97 billion OptionableOptionable Beta-0.01 2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (NASDAQ:ECYT) was last updated on 7/6/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredWhy Elon is funding the “Quantum Power Grid”Elon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredDalio heeds Buffett’s warning… [$319 million stake in gold]Dalio bought a gold ETF… I don’t recommend that for the average retail investor. The real upside is in profita...Golden Portfolio | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Endocyte, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Endocyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.